Exacerbation of financial burden of insulin and overall glucose-lowing medications among uninsured population with diabetes.

For insured people, the rising financial burden of insulin was borne mainly by insurance. The uninsured population is bearing a heavy burden due to the high price of insulin. Policymakers should take action to reduce the insulin price and improve the transparency of the insulin pricing process.